34th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100216717 | Hypoallergenic Mutant Polypeptides Based on Fish Parvalbumin - The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination. | 2010-08-26 |
20100216718 | Cancer Classification and Methods of Use - The present invention relates to methods of classifying cancer cells based on the presence, absence or level of a tyrosine kinase or a phosphorylated tyrosine kinase. The present invention also relates to methods of treating cancer using cancer classification. The present invention further relates to methods of determining the effectiveness of a treatment for cancer using cancer classification. | 2010-08-26 |
20100216719 | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health - A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including a purified glucomannan and at least one galactomannan. A method for treating or offsetting the risks of such a disease or disorder includes the step of administering to a human in need thereof an effective amount of the pharmaceutical composition to treat the cardiovascular disease. | 2010-08-26 |
20100216720 | ANTIBODIES TO TROPONIN I AND METHODS OF USE THEREOF - The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome. | 2010-08-26 |
20100216721 | Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120 - The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. | 2010-08-26 |
20100216722 | USE OF THE PEPTIDE PRO-GLY-THR-CYS-GLU-ILE-CYS-ALA-TYR-ALA-ALA-CYS-THR-GLY-CYS AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-26 |
20100216723 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS - This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease. | 2010-08-26 |
20100216724 | USE OF FIBRONECTIN FRAGMENT (196-203 ) AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ser-Arg-Asn-Arg-Cys-Asn-Asp-Gln-NH | 2010-08-26 |
20100216725 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides of Formula I | 2010-08-26 |
20100216726 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof - The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound. | 2010-08-26 |
20100216727 | Carbohydrate-metallocene-antimalarial conjugates - An antimalarial conjugate according to a non-limiting embodiment of the present invention may include a metallocene, a carbohydrate, and an antimalarial agent. The metallocene may include two cyclopentadienyl rings bound to a central metal atom. The carbohydrate and the antimalarial agent may be appended to at least one of the cyclopentadienyl rings of the metallocene, wherein the antimalarial agent has therapeutic properties directed to treating and/or preventing malaria. The metallocene may be ferrocene, the carbohydrate may be glucose, and the antimalarial agent may be chloroquine. | 2010-08-26 |
20100216728 | NEW USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin. | 2010-08-26 |
20100216729 | Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts - A group of phytochemical compounds extracted from whole germinated or not germinated black beans ( | 2010-08-26 |
20100216730 | SPRAYABLE CONTROLLED-RELEASE, MALE ANNIHILATION TECHNIQUE (MAT) FORMULATION AND INSECT CONTROL - A male annihilation insecticide formulation, having a viscosity appropriate for use in aerial or backpack spray applications and suitable for on-crop or off-crop uses, comprises an insect toxicant and a male-specific attractant, such as a parapheromone, for a target insect species, such as fruit fly, dispersed and entrapped in an emulsion comprising a biodegradable wax, an emulsifiers, and water. | 2010-08-26 |
20100216731 | PROCESS FOR THE PREPARATION OF MACROLIDE ANTIBACTERIAL AGENTS - Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof. | 2010-08-26 |
20100216732 | Azithromycin for the treatment of nodular acne - Azithromycin, administered systemically, is an effective treatment for nodules associated with acne vulgaris. | 2010-08-26 |
20100216733 | Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis - The present invention relates to a method for treating proliferative mastocytosis comprising administering a Bruton tyrosine kinase (BTK) inhibitor, a BTK antisense to a mammal in need of such treatment. The invention is more particularly suited for treating category II, III and IV mastocytosis. | 2010-08-26 |
20100216734 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use nootropic agents, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells. | 2010-08-26 |
20100216735 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY - Disclosed are methods of preventing or treating neuronal damage associated with oxidative stress and/or neuronal injury. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to increase the extracellular concentration of said agonist in the brain of the subject such that at least a portion of cell surface P2Y receptors expressed by astrocytes are activated to mount a neuroprotective response. The pharmaceutical composition may be administered orally or parenterally. The pharmaceutical composition with typically be administered to an individual within at least one hour of the event that caused oxidative stress in the subject. The pharmaceutical composition includes a P2Y purinergic receptor agonist, which can include uridine 5′-di- and triphosphate (UDP, UTP) and their analogs, adenosine 5′-diphosphate (ADP) and its analogs, cytidine 5′-di- and triphosphate (CDP, CTP) and their analogs, and dinucleoside polyphosphate compounds. | 2010-08-26 |
20100216736 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND -
The present invention provides a pyrimidine nucleoside compound represented by the following formula (1):
| 2010-08-26 |
20100216737 | Inactivation of miR-34a by abberant CpG methylation in cancer - The present application refers to methods for cancer diagnosis and treatment, particularly in types of cancers associated with aberrant CpG methylation of the miR-34a promoter. | 2010-08-26 |
20100216738 | Acaricidal Active Substance Combinations - The present invention relates to the use of active substance combinations which consist firstly of a known dihydrofuranone derivative and secondly of further known pesticidal active substances, which active substance combinations are used for controlling animal pests, in particular from the order of the mites. | 2010-08-26 |
20100216739 | METHOD OF PROMOTING MUSCLE TISSUE REPAIR - A method of treating a muscle tissue which is effected by providing the muscle tissue with an effective amount of a sterile polymer solution being essentially devoid of free multivalent cations and being capable of self-gelling following deposition in or around the muscle tissue. | 2010-08-26 |
20100216740 | Cereal-based Infant Nutrition with Fibre - Cereal-based semi-liquid and/or semi-solid compositions suitable for supporting the transition period wherein the infant changes from a diet consisting of breast milk or liquid infant formula to solid adult foods, comprising uronic acid carbohydrates with a degree of polymerisation (DP) between 10 and 300 and also uses thereof are disclosed. | 2010-08-26 |
20100216741 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) one or more member(s) selected from the group consisting of chondroitin sulfate, alginic acid and salts thereof; and (C) a nonionic surfactant. | 2010-08-26 |
20100216742 | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health - A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including a purified glucomannan and at least one galactomannan. A method for treating or offsetting the risks of such a disease or disorder includes the step of administering to a human in need thereof an effective amount of the pharmaceutical composition to treat the cardiovascular disease. | 2010-08-26 |
20100216743 | THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition. | 2010-08-26 |
20100216744 | THICKENER/GELLANT FOR OILY SUBSTANCE - The purpose of the invention is to provide a thickening and gelling agent that is easily dispersed into an oily substance such as a silicone oil in a small addition amount, is free of liquid separation, stably forms a thickened material or a gel state, and can prepare a thickened product or a gel having spreadability and free of sticky feeling and dry feeling. The invention provides a thickening and gelling agent for an oily substance containing the components (A) a modified product of alkoxytitanium or alkoxyzirconium with a carboxylic acid and a hydroxy compound, and (B) at least one silicone oil selected from a silicone oil having an amino group and a silicone oil having a carboxyl group; an oily composition and a cosmetic preparation, containing the thickening and gelling agent. | 2010-08-26 |
20100216745 | NOVEL CEPHEM COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIONS - The present invention relates to new cephem compounds useful for the treatment of bacterial infections. The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections. | 2010-08-26 |
20100216746 | CHEMICAL COMPOUNDS - The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection. | 2010-08-26 |
20100216747 | PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY ABNORMAL BONE METABOLISM - An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively. | 2010-08-26 |
20100216748 | Pyrrole Derivatives and Their Methods of Use - The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions. | 2010-08-26 |
20100216749 | Combination Therapy for Neuroprotection - The present invention relates to combination therapy of a pyruvoyl derivative and an anti-oxidant, which is characterized by significant increase of the activity of microglia, inhibition of brain tissue damage by the activation of inflammatory cytokines, improvement of motor skill and recovery effect of neuronal damage. Compared to single treatment with each, this present invention provides a continuous high neuroprotective effect even after 6 hours from the onset of damage. | 2010-08-26 |
20100216750 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE - A series of substituted oxazole compounds having an alpha keto side chain at the 2 position and an aromatic, heteroaromatic or heterocycle substituent at the 5 position are disclosed. These compounds exhibit inhibition of fatty acid amid hydrolase and arc useful for treatment of malconditions involving that enzyme. | 2010-08-26 |
20100216751 | Liquid Bevirimat Dosage Forms for Oral Administration - The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments. | 2010-08-26 |
20100216752 | USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS - A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I | 2010-08-26 |
20100216753 | CONTROLLED RELEASE OF DRUGS INTO/THROUGH THE SKIN - The slow and sustained, controlled release of a drug into and through the skin includes topically applying onto the skin of an individual in need of such treatment, a composition containing at least one solubilized drug, at least one film-forming silicone, and at least one volatile solvent. | 2010-08-26 |
20100216754 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT - Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2010-08-26 |
20100216755 | ANTI-TUMOR AGENT - The present application provides a method for the treatment of tumors where the lethal dose of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is increased to twice or more, the toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, hepatic toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, and/or cardiovascular toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, by administering to a subject in need thereof a composition containing:
| 2010-08-26 |
20100216756 | COMPOSITIONS AND METHODS FOR SUPPRESSING ENDOMETRIAL PROLIFERATION - The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment. | 2010-08-26 |
20100216757 | Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase - A process for improving the penetration of at least one pharmaceutical active agent into the skin, including formulating at least one volatile silicone, a non-volatile oily phase and a pharmaceutically acceptable alcoholic vehicle herewith, and spraying the formulation onto the skin of an individual in need of such treatment. | 2010-08-26 |
20100216758 | Pyridone Compounds - An active ingredient is a compound represented by the general formula [I]: | 2010-08-26 |
20100216759 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia - Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described. | 2010-08-26 |
20100216760 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - Disclosed herein are cannabinoid receptor ligands of formula (I) | 2010-08-26 |
20100216761 | NOVEL AZETIDINONES USEFUL AS INHIBITORS OF ELASTASE - The invention is directed to novel azetidinones selected from 2-(S)-[4-(((2-(Dimethylamino)ethyl)ethylamino)carbonyl)phenoxy]-3,3-diethyl-N-[1-(R)-(4-(trifluoromethoxy)phenyl)butyl]-4-oxo-1-azetidin ecarboxamide, 2-(S)-[4-(((2-(Dimethylamino)ethyl)ethylamino)carbonyl)phenoxy]-3,3-diethyl-N-[1-(R)-(4-(trifluoromethyl)phenyl)butyl]-4-oxo-1-azetidinecarboxamide, and analogs thereof, and pharmaceutically acceptable salts thereof, and their use in the treatment of diseases associated with an excess of elastase, including emphysema, bronchial inflammation, chronic bronchitis, cystic fibrosis, acute respiratory distress syndrome, rheumatoid arthritis, osteoarthritis; glomerulonephritis, spondylitis, lupus, psoriasis, atherosclerosis, sepsis, septicemia, shock, myocardial infarction, reperfusion injury, and periodontitis. | 2010-08-26 |
20100216762 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof - Disclosed are compounds that are agonists or antagonists of the S1P | 2010-08-26 |
20100216763 | Heteroaryl Amide Derivatives - Heteroaryl amide derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. | 2010-08-26 |
20100216764 | Soluble Guanylate Cyclase Activators - This inventions relates to compounds having the structure Formula I | 2010-08-26 |
20100216765 | KINASE INHIBITORS - Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of: | 2010-08-26 |
20100216766 | Inhibitors of VEGF Receptor and HGF Receptor Signalling - The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions | 2010-08-26 |
20100216767 | QUINAZOLINES FOR PDK1 INHIBITION - The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions. | 2010-08-26 |
20100216768 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE - The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2010-08-26 |
20100216769 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS - The present invention relates to new substituted glycinamides of general formula (I) | 2010-08-26 |
20100216770 | Inhibitors of the Interaction Between MDM2 and P53 - The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: | 2010-08-26 |
20100216771 | METHOD OFTREATING DEMYELINATION DISEASES - The present invention relates to a method of treating demyelination diseases, such as multiple sclerosis, comprising administration of an atypical antipsychotic drug, such as quetiapine or an analog thereof, to a subject in need thereof. | 2010-08-26 |
20100216772 | Novel Phenantridine Analogues and Uses Thereof - The present invention relates to compounds of the general formula (IV) and (II) and salts and physiologically functional derivatives thereof, | 2010-08-26 |
20100216773 | PHENANTHROINDOLIZIDINE ANALOGUES - Treatment of coronavirus infection with phenanthroindolizidine analogues. | 2010-08-26 |
20100216774 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2010-08-26 |
20100216775 | Adamantanamines and Neramexane Salts of Thiomolybdic and Thiotungstic Acids - This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's, Huntington's, AIDS-related dementia and Schizophrenia and its cognitive deficits. Additional uses of these derivatives include antiviral activity. The novel compositions of the present invention appear particularly useful in enhancing the therapeutic benefits of copper-sequestering tetrathiomolybdates in treating elevated copper-induced toxicities in neurologically presenting Wilson's disease, and in treating diseases of the inflammatory etiology and abnormal copper biochemistry, such as tumor angiogenesis, liver cirrhosis, hepatitis, pulmonary fibrosis and other fibrotic diseases, cardiovascular disease, cerebral ischemia, renal anemia, rheumatoid arthritis, diabetes, obesity, gastrointestinal disorders, and eye diseases such as glaucoma, proliferative diabetic retinopathy, and age related macular degeneration. These compounds have excellent stability and aqueous solubility for good oral bioavailability. | 2010-08-26 |
20100216776 | Assays for S100 inhibitors - Provided are methods of determining whether a compound is an inhibitor of an S | 2010-08-26 |
20100216777 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS - Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed. | 2010-08-26 |
20100216778 | PAIN REMEDY CONTAINING ROCK INHIBITOR - Since a ROCK inhibitor exerts a potent analgesic effect by a single dose after the onset of a cartilage-related disease such as osteoarthritis, and can regenerate or suppress destruction of cartilage tissue and alleviate pain associated with cartilage diseases by multiple doses, administration of an therapeutically effective amount of the ROCK inhibitor to a patient with cartilage-related disease such as osteoarthritis or rheumatoid arthritis can treat the patient with cartilage-related disease and the ROCK inhibitor is thus useful. | 2010-08-26 |
20100216779 | Imidazopyridine Kinase Inhibitors - The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents. | 2010-08-26 |
20100216780 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE - This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. | 2010-08-26 |
20100216781 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 2010-08-26 |
20100216782 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 - This invention provides methods for treating, alleviating or reducing the incidence of a disease or condition comprising or arising from abnormal cell growth in a mammal, which comprise administering to the mammal a compound, salt, hydrate, tautomer or N-oxide according to formula (I): | 2010-08-26 |
20100216783 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES - The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression. | 2010-08-26 |
20100216784 | Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds - Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells. | 2010-08-26 |
20100216785 | PHARMACEUTICAL COMPOSITIONS - Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%:
| 2010-08-26 |
20100216786 | NEW COMPOUNDS - The present invention relates to the adenosine A | 2010-08-26 |
20100216787 | THIAZOLE DERIVATIVE - A thiazolylimidazole derivative represented by the formula | 2010-08-26 |
20100216788 | FUSED HETEROCYCLIC COMPOUND - The present invention provides a compound represented by the formula: | 2010-08-26 |
20100216789 | RHO-KINASE INHIBITORS - Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. | 2010-08-26 |
20100216790 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS - The compounds of formula (I) | 2010-08-26 |
20100216791 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS - The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 2010-08-26 |
20100216792 | Pesticidal arylpyrrolidines - The invention is directed to arylpyrrolidines compounds which exhibit excellent insecticidal efficacy and which may be used as in the agrochemical field or in the field of veterinary medicine. The compounds are represented by formula (I): | 2010-08-26 |
20100216793 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES - The present invention is concerned with novel pyridazinone derivatives of formula (I) | 2010-08-26 |
20100216794 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS - Novel heterocyclic compounds of the formula I | 2010-08-26 |
20100216795 | TNIK INHIBITOR AND THE USE - The present invention relates to Traf2- and Nck-interacting kinase (TNIK) inhibitors, pharmaceutical compositions, and methods for the treatment of cancer patients with TNIK inhibitors. | 2010-08-26 |
20100216796 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS - The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to treat cancer. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives in vivo. | 2010-08-26 |
20100216797 | PREPARATION OF THIOARABINOFURANOSYL COMPOUNDS AND USE THEREOF - Patients suffering from cancer are treated by being administered a compound represented by the following formula: | 2010-08-26 |
20100216798 | FUSED HETEROCYCLES AS LCK INHIBITORS - There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. | 2010-08-26 |
20100216799 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I), | 2010-08-26 |
20100216800 | Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione - This invention relates to a therapeutic method for glycaemic control, in particular to a method for the treatment of type 2 diabetes, comprising the administration of a DPIV inhibitor together with metformin or a thiazolidinedione. | 2010-08-26 |
20100216801 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones. | 2010-08-26 |
20100216802 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER - Compound of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful in treatment of cell proliferative diseases: | 2010-08-26 |
20100216803 | ORNITHINE DERIVATIVE - Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. | 2010-08-26 |
20100216804 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 2010-08-26 |
20100216805 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS - The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure provides compositions and methods based on the use of D-cycloserine in combination with the neurogenic agent, which synergistically stimulates or activates the formation of new nerve cells. | 2010-08-26 |
20100216806 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER - Compounds of formula | 2010-08-26 |
20100216807 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF - Novel heterocyclic compounds of formula I: | 2010-08-26 |
20100216808 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2010-08-26 |
20100216809 | PIPERIDINE/PIPERAZINE DERIVATIVES - The invention further relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —NR | 2010-08-26 |
20100216810 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. | 2010-08-26 |
20100216811 | FURO[3. 2-B] PYRROL DERIVATIVES - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R | 2010-08-26 |
20100216812 | Cyclopropyl Amide Derivatives - Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith. | 2010-08-26 |
20100216813 | PYRROLIDINEANILINES - The present invention relates to a compound represented by the following formula I or a pharmaceutically acceptable salt thereof; wherein R | 2010-08-26 |
20100216814 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES - This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2010-08-26 |
20100216815 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. | 2010-08-26 |
20100216816 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to pyrazinyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 2010-08-26 |